GSK (MEX:GSK1N) Cyclically Adjusted Revenue per Share: MXN162.53 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GSK1N GSK PLC MEX:GSK1N
75 GF Score
Price MXN426.27
GF Value MXN305.38
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Cyclically Adjusted Revenue per Share?

GSK MEX:GSK1N 75 Cyclically Adjusted Revenue per Share is MXN162.53 as of Jun. 2026. GuruFocus rates MEX:GSK1N with a GF Score™ of 75/100 and a GF Value™ of MXN305.38 (Significantly Overvalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

GSK's adjusted revenue per share for the three months ended in Jun. 2026 was MXN48.163. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN162.53 for the trailing ten years ended in Jun. 2026.

During the past 12 months, GSK's average Cyclically Adjusted Revenue Growth Rate was 1.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 2.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 3.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 2.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of GSK was 9.10% per year. The lowest was 0.60% per year. And the median was 4.20% per year.

As of today (2026-08-15), GSK's current stock price is MXN426.27. GSK's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN162.53. GSK's Cyclically Adjusted PS Ratio of today is 2.62.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.49. The lowest was 1.48. And the median was 2.01.


GSK  (MEX:GSK1N) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

GSK's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=426.27/162.53
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of GSK was 2.49. The lowest was 1.48. And the median was 2.01.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


GSK Cyclically Adjusted Revenue per Share Related Terms


GSK Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for GSK's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Cyclically Adjusted Revenue per Share Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 191.14 247.46 176.90 236.91 174.71

GSK Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.27 201.32 174.71 154.78 162.53

MEX:GSK1N vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, GSK's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GSK Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where GSK's Cyclically Adjusted PS Ratio falls into.


MEX:GSK1N
75GF Score
GSK PLC MEX:GSK1N
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GSK's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=48.163/142.3000*142.3000
=48.163

Current CPI (Jun. 2026) = 142.3000.

GSK Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 48.865 101.500 68.507
201612 49.238 102.200 68.557
201703 43.627 102.700 60.449
201706 43.334 103.500 59.579
201709 48.070 104.300 65.584
201712 50.570 105.000 68.534
201803 46.322 105.100 62.718
201806 48.127 105.900 64.669
201809 49.743 106.600 66.402
201812 51.076 107.100 67.863
201903 49.165 107.000 65.385
201906 47.615 107.900 62.795
201909 57.246 108.400 75.149
201912 54.329 108.500 71.254
202003 65.816 108.600 86.240
202006 54.810 108.800 71.686
202009 61.361 109.200 79.960
202012 -6.660 109.400 -8.663
202103 52.191 109.700 67.701
202106 40.364 111.400 51.560
202109 46.171 112.400 58.453
202112 47.532 114.700 58.970
202203 46.389 116.500 56.662
202206 33.794 120.500 39.908
202209 43.627 122.300 50.761
202212 42.825 125.300 48.635
202303 37.222 126.800 41.772
202306 37.962 129.400 41.746
202309 42.712 130.100 46.717
202312 41.992 130.500 45.789
202403 37.751 131.600 40.820
202406 44.580 133.000 47.697
202409 50.393 133.500 53.715
202412 51.483 135.100 54.227
202503 48.021 136.100 50.209
202506 49.642 138.400 51.041
202509 51.652 138.900 52.916
202512 50.901 139.900 51.774
202603 45.024 140.800 45.504
202606 48.163 142.300 48.163

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN162.53 mean?
GSK (MEX:GSK1N) has a Cyclically Adjusted Revenue per Share of MXN162.53 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GSK and its competitors.
Is GSK's Cyclically Adjusted Revenue per Share too high?
GSK's current Cyclically Adjusted Revenue per Share is MXN162.53. Overall, GSK has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
GSK's Cyclically Adjusted Revenue per Share of MXN162.53 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on GSK and its competitors. GSK's current Cyclically Adjusted Revenue per Share is MXN162.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSK1N) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN305.38, compared to a current price of MXN426.27 — trading 39.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN162.53. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For GSK (MEX:GSK1N), the current Cyclically Adjusted Revenue per Share is MXN162.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (MEX:GSK1N) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of MXN426.27 is trading 39.6% above its estimated GF Value™ of MXN305.38. GuruFocus considers GSK to be Significantly Overvalued.

Key valuation signals for MEX:GSK1N:

  • Cyclically Adjusted Revenue per Share: MXN162.53
  • GF Value™: MXN305.38 vs. price of MXN426.27 (39.6% above fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the MEX:GSK1N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score

Get the complete analysis for MEX:GSK1N

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN426.27
Price
MXN305.38
GF Value